Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Gastrointestinal disorders – page 85

  • 1 123 clinical trials
  • 490 recruiting
  • 469 conditions
  • 28 countries

Conditions in this area

469 conditions with trials, the busiest first

Colitis ulcerative120Colorectal cancer metastatic105Crohn's disease94Colorectal cancer89Pancreatic carcinoma57Gastric cancer55Oesophageal adenocarcinoma48Systemic scleroderma39Pancreatic carcinoma metastatic35Adenocarcinoma pancreas34Rectal cancer33Oesophageal carcinoma32Sjogren's syndrome29Adenocarcinoma gastric28Ovarian cancer27Non-small cell lung cancer26Breast cancer25Colon cancer25Gastrooesophageal cancer25Cystic fibrosis24Hepatocellular carcinoma18Fallopian tube cancer17Endometrial cancer16Gastroenteropancreatic neuroendocrine tumour disease16+445

Clinical trials in Gastrointestinal disorders

1 123 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 123 clinical trials

Colitis ulcerative

Not recruiting

Study on the Effects of GS-5290 for Patients with Moderate to Severe Ulcerative Colitis

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:(Phosphonooxy)Methyln-[(S)-[1-(Bicyclo[1.1.1]Pentan1-Yl)-1H-1,2,3-Triazol-4-Yl](2-Methyl-1-Oxo-1,2-Dihydroisoquinolin-5-Yl)Methyl]-N-{8-Chloro-3-Cyano-4-[(2,2-Dimethylpropyl)Amino]Quinolin-6-Yl]Carbamate
  • Sponsor:Gilead Sciences Inc.

Dyspepsia+1

Not recruiting

Study on Juniper Berry Oil for Digestive Issues like Cramps, Gas, and Bloating in Adults

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Juniper Berry Oil
  • Sponsor:CGBS GbR

Cystic fibrosis

Not recruiting

Study on VX-522 and Ivacaftor for Adults with Cystic Fibrosis Unresponsive to CFTR Modulator Therapy

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Ivacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pf-06480605
  • Sponsor:F. Hoffmann-La Roche AG

Eosinophilic gastritis

Not recruiting

Study on the Safety and Effectiveness of Dupilumab for Adults and Adolescents with Eosinophilic Gastritis and Eosinophilic Duodenitis

Registered drug
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Constipation

Not recruiting

Study on Linaclotide for Treating Functional Constipation in Children Aged 6 Months to Less Than 2 Years

Registered drug
Countries:BulgariaBulgaria
  • Participants:0–17 years
  • Substances:Linaclotide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Dry eye+1

Not recruiting

Study on Long-Term Safety and Efficacy of Ianalumab for Patients with Sjögren’s Syndrome

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Oesophageal adenocarcinoma

Not recruiting

Study of Sacituzumab Govitecan for Patients with Advanced Esophagogastric Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sacituzumab Govitecan
  • Sponsor:Institut fuer Klinische Krebsforschung IKF GmbH

Colitis ulcerative

Not recruiting

Study on Upadacitinib for Children with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Crohn's disease

Not recruiting

Study on the Long-Term Safety and Effectiveness of Upadacitinib for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Endometrial cancer+6

Not recruiting

Study on Pembrolizumab, Lenvatinib, and Belzutifan for Patients with Liver, Colon, Pancreatic, Bile Duct, Gallbladder, Endometrial, or Esophageal Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Colorectal adenocarcinoma

Not recruiting

Study on the Effectiveness and Safety of Cetuximab, Encorafenib, and Binimetinib for Patients with Advanced Colorectal Cancer with BRAF V600E Mutation

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib
  • Sponsor:Asociacion Grupo Tratamiento De Tumores Digestivos

Substances studied in this area

The therapies tested most often in Gastrointestinal disorders trials.

Fluorouracil205 clinical trialsOxaliplatin195 clinical trialsCapecitabine108 clinical trialsFolinic Acid83 clinical trialsBevacizumab72 clinical trialsCalcium Folinate67 clinical trialsPembrolizumab57 clinical trialsIrinotecan Hydrochloride Trihydrate52 clinical trialsNivolumab48 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.